Recently, a U.S. senator formally launched a comprehensive investigation into the Food and Drug Administration (FDA) approval decision-making process. This investigation directly targets the FDA's rigid stance in handling treatment applications for rare diseases. According to Bloomberg, this U.S. senator has raised serious questions about the efficiency and transparency of the American regulatory agency in evaluating innovative therapies, claiming that existing procedures may be hindering the emergence of treatment options that could save patients' lives.

The U.S. senator's investigation focuses on several key issues: First, what factors have led the FDA to reject treatment applications for rare medical conditions at an unusually high frequency; Second, whether the current FDA approval mechanism truly incentivizes medical innovation or is actually stifling industry development; Third, whether the mechanism for patient access to potentially life-saving treatments is sufficiently transparent and efficient.

This policy review from the U.S. senator comes at a sensitive time—American society's attention to medical regulatory practices is growing. The public, medical professionals, and pharmaceutical companies are all questioning the FDA's decision-making process to varying degrees, particularly those applications involving rare disease treatments. The U.S. senator's action reflects calls from American policymakers for establishing a more balanced regulatory framework that both ensures drug safety and provides patients with timely access to innovative therapies.

The investigation is expected to conduct an in-depth review of FDA internal processes and assess whether they align with the fundamental mission of promoting medical innovation and protecting patient interests.